文献速递眼底病与葡萄膜炎

中间型年龄相关性黄斑变性中持续性脉络膜高透射缺损的出现与进展:一种新的临床试验终点

Onset and Progression of Persistent Choroidal Hypertransmission Defects in Intermediate Age-Related Macular Degeneration: A Novel Clinical Trial Endpoint.
PubMed 文献 · Am J Ophthalmol · 2023-03-22

本研究对前瞻性研究中的中间型年龄相关性黄斑变性(iAMD)眼进行事后亚组分析,利用en face扫频源OCT血管成像检测持续性脉络膜高透射缺损(hyperTD)。171眼中68眼出现至少1个hyperTD,出现后1年内25%的眼出现新hyperTD,2年内平均面积增长率为0.220 mm/yr。作者提出hyperTD的出现和扩大可作为iAMD疾病进展研究的临床试验终点。

要点

  • iAMD眼在en face SS-OCT上可检测到持续性脉络膜高透射缺损(hyperTD)。
  • 出现hyperTD后1年内25%的眼出现新hyperTD,平均新增0.44个。
  • 2年内hyperTD平均面积增长率为0.220 mm/yr(平方根变换策略)。

核心结论

  • iAMD眼中持续性脉络膜高透射缺损的出现和生长可通过en face OCT成像轻松检测和测量,可作为研究延缓iAMD向晚期AMD进展的疗法的新的临床试验终点。

研究设计与样本

  • 前瞻性研究的事后亚组分析。
  • 纳入121例iAMD患者的171眼,在基线和随访时进行6×6 mm SS-OCT血管成像,由两名分级者独立评估en face结构图像中持续性hyperTD的存在。
  • 使用经过验证的SS-OCT算法获取玻璃膜疣体积,一旦发生渗出性AMD即终止进一步随访。

主要发现

  • 171眼中68眼出现至少1个hyperTD。
  • 出现hyperTD后1年内,25%的眼出现新hyperTD,平均新增0.44个hyperTD。
  • 2年内随着hyperTD出现、扩大和融合,采用平方根变换策略的平均面积增长率为0.220 mm/yr。

关键数值与推荐

  • 持续性脉络膜高透射缺损(hyperTD)作为iAMD临床试验终点的相关参数:出现后1年内25%的眼出现新hyperTD,平均新增0.44个;2年平均面积增长率为0.220 mm/yr。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The appearance and growth of persistent choroidal hypertransmission defects (hyperTDs) detected on en face swept-source optical coherence tomography (SS-OCT) images from eyes with intermediate age-related macular degeneration (iAMD) were studied to determine if they could serve as novel clinical trial endpoints. DESIGN: Post hoc subgroup analysis of a prospective study. METHODS: Subjects with iAMD underwent 6 × 6 mm SS-OCT angiography imaging at their baseline and follow-up visits. The drusen volumes were obtained using a validated SS-OCT algorithm. Two graders independently evaluated all en face structural images for the presence of persistent hyperTDs. The number and area of all hyperTDs along with drusen volume were obtained from all SS-OCT angiography scans. Eyes were censored from further follow-up once exudative AMD developed. RESULTS: A total of 171 eyes from 121 patients with iAMD were included. Sixty-eight eyes developed at least 1 hyperTD. Within 1 year after developing a hyperTD, 25% of eyes developed new hyperTDs for an average of 0.44 additional hyperTDs. Over 2 years, as hyperTDs appeared, enlarged, and merged, the average area growth rate was 0.220 mm/yr using the square-root transformation strategy. A clinical trial design using the onset and enlargement of these hyperTDs for the study of disease progression in eyes with iAMD is proposed. CONCLUSIONS: The appearance and growth of persistent choroidal hyperTDs in eyes with iAMD can be easily detected and measured using en face OCT imaging and can serve as novel clinical trial endpoints for the study of therapies that may slow disease progression from iAMD to late AMD.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Liu J, Shen M, Laiginhas R, et al. Onset and Progression of Persistent Choroidal Hypertransmission Defects in Intermediate Age-Related Macular Degeneration: A Novel Clinical Trial Endpoint. Am J Ophthalmol. 2023. PMID: 36958537. doi:10.1016/j.ajo.2023.03.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。